Article

Rociletinib for EGFR-mutated Non–Small-Cell Lung Cancer

2015-04-29

Abstract excerpt

In patients with non–small-cell lung cancer (NSCLC), resistance to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is usually mediated by the T790M EGFR gene mutation. Rociletinib is an oral EGFR mutant-selective inhibitor that has demonstrated activity against EGFR -mutated NSCLC with or without T790M mutation. Investigators have now conducted an industry-supported, ph...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d00aff87-1b22-588d-8869-a6dce0e404e5
DOI: 10.1056/nejm-jw.na37701

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Rociletinib for EGFR-mutated Non–Small-Cell Lung CancerDOI 10.1056/nejm-jw.na37701Read

Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.Semantic proximity Read

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.Semantic proximity Read

[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].Semantic proximity Read

Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung CancerSemantic proximity Read

Rociletinib in EGFR-mutated non-small-cell lung cancer.Semantic proximity Read

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerSemantic proximity Read

3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvementSemantic proximity Read

Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions.Semantic proximity Read

Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study.Semantic proximity Read

6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)Semantic proximity Read

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.Semantic proximity Read

First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer.Semantic proximity Read